Related Experiment Videos

Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative

K Pajusola1, O Aprelikova, E Armstrong

  • 1Department of Pathology, University of Helsinki, Finland.

Oncogene
|November 1, 1993
PubMed

Insights

The FLT4 gene produces two distinct protein forms, short (FLT4s) and long (FLT4l), through alternative RNA processing. These variants, differing in their C-terminal tails, may impact vascular endothelial growth factor receptor signaling.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cell Biology

Background:

  • FLT4 is a gene encoding a transmembrane tyrosine kinase, part of the vascular endothelial growth factor receptor family.
  • Previous studies identified FLT4 transcripts of 4.5 and 5.8 kb in human tissues.

Purpose of the Study:

  • To investigate the molecular basis for the two FLT4 transcripts.
  • To determine the structural differences between the polypeptides encoded by these transcripts.
  • To elucidate the regulatory mechanisms generating FLT4 variants.

Main Methods:

  • Analysis of gene expression in transfected and leukemia cells.
  • Comparison of 3' coding regions of 4.5 kb and 5.8 kb FLT4 mRNA.
  • Genomic structure analysis of the carboxy-terminal encoding region.

Main Results:

  • The 4.5 kb and 5.8 kb transcripts encode short (FLT4s) and long (FLT4l) polypeptides, respectively.
  • FLT4s and FLT4l possess distinct carboxy-terminal tails.
  • Alternative polyadenylation and splicing generate the two FLT4 transcript variants.
  • The FLT4 long form contains additional potential autophosphorylation sites.

Conclusions:

  • FLT4 protein structure is regulated at the post-transcriptional level via alternative polyadenylation and splicing.
  • The distinct C-terminal tails of FLT4s and FLT4l may confer differential functions.
  • The presence of extra autophosphorylation sites in FLT4l could influence receptor signaling pathways.

Related Concept Videos